Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2007

View Archived Issues

Recent clinical data on nilotinib in leukemia presented

Snapshots of agents under study in Alzheimer's disease

Malaria vaccine AMA1 studied in phase Ib trial in Mali

New results with therapies under development for Parkinson's disease

Recent Tibotec and Bristol-Myers Squibb patents report novel therapeutic agents for HIV infection

New agents for treating neurological disorders disclosed in recent patent literature

Recent patents report novel therapeutic agents for metabolic disorders

NOV-002 slows disease progression in platinum-resistant ovarian cancer

Positive topline findings for balsalazide tablets

FDA grants orphan drug status to Immtech's pafuramidine

Keryx completes patient randomization for Sulonex phase III study

Chugai to explore safety of oseltamivir

Findings for new powder form of Renvela

IC31 adjuvanted flu vaccine begins phase I trials

Lexicon announces long-term financial agreements with Invus and Symphony

Peptech restructures agreement with Biosceptre

Sativex receives Qualifying Notice from Health Canada for cancer pain

Genta to request review of Genasense's non-approvable status

Collegium files IND for abuse deterrent opioid COL-003

Terutroban exhibits beneficial effects in rat models of stroke

FDA accepts for review GlaxoSmithKline's DTaP-IPV combination vaccine

Preclinical studies on drugs under development for Parkinson's disease

Telcyta clinical hold converted to partial hold

Nexavar submitted in E.U. for hepatocellular carcinoma

Ixabepilone NDA granted priority review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...